Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?

被引：0
|
作者：
Keizman, Daniel
Ish-Shalom, Maya
Maimon, Natalie
Gottfried, Maya
Pili, Roberto
Hammers, Hans J.
Eisenberger, Mario A.
Sinibaldi, Victoria J.
Boursi, Ben
Weitzen, Rony
Hayat, Henry
Peer, Avivit
Neumann, Avivit
Kovel, Svetlana
Sella, Avishay
Mermershtain, Wilmosh
Rouvinov, Keren
Berger, Raanan
Carducci, Michael Anthony
机构：
[1] Tel Aviv Univ, Genitourinary Oncol Serv, Div Oncol, Meir Med Ctr,Sackler Sch Med, Kefar Sava, Israel
[2] Meir Med Ctr, Lung Canc Unit, Kefar Sava, Israel
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] Chaim Sheba Med Ctr, Ramat Gan, Israel
[7] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
[8] Wolfson Med Ctr, Dept Oncol, Holon, Israel
[9] Rambam Hlth Care Campus, Haifa, Israel
[10] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[11] Asaf Harofe Med Ctr, Dept Oncol, Zerifin, Israel
[12] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel
[13] Soroka Med Ctr, Beer Sheva, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15598
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Correlation between patient-reported fatigue and hemoglobin (Hgb) levels in metastatic renal cell carcinoma (mRCC) patients (pts) receiving sunitinib (SU).
    Davis, Mellar P.
    Matczak, Ewa M.
    Chen, Connie
    Korytowsky, Beata
    Bhattacharyya, Helen
    Lin, Xun
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [42] Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease treated with sunitinib.
    Keizman, Daniel
    Ish-Shalom, Maya
    Taksey, Jason David
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Boursi, Ben
    Berger, Raanan
    Maimon, Natalie
    Gottfried, Maya
    Hayat, Henry
    Peer, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Carducci, Michael Anthony
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [43] Predictive biomarkers in metastatic Renal Cell Carcinoma (mRCC) patients treated with neoadjuvant sunitinib (PREINSUT trial)
    Mauge, L.
    Pereira, H.
    Gille, A. S.
    Bouaboula, M.
    Grine, A.
    Elaidi, R. T.
    Tartour, E.
    Fournier, L.
    Oudard, S.
    Helley, D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S34 - S34
  • [44] SAFETY PROFILE OF SUNITINIB AND SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Massari, Francesco
    Sperandi, Francesca
    Cricca, Antonia
    Melotti, Barbara
    Martoni, Andrea Angelo
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [45] Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC).
    Houk, B. E.
    Amantea, M.
    Motzer, R. J.
    Michaelson, M. D.
    Rini, B. I.
    George, D. J.
    Redman, B. G.
    Hudes, G. R.
    Poland, B.
    Bello, C. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [46] Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC)
    George, D. J.
    Michaelson, M. D.
    Rosenberg, J. E.
    Redman, B. G.
    Hudes, G. R.
    Bukowski, R. M.
    Kim, S. T.
    Chen, I.
    Wilding, G.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 304 - 304
  • [47] Relation between lactate dehydrogenase (LDH) during two first cycles in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU)
    Medioni, J.
    Arakelian, N.
    Fournier, L.
    Helley, D.
    Thiam, R.
    Banu, E.
    Cuenod, C.
    Oudard, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Gordon, M. S.
    Stein, M.
    Shannon, P.
    Eddy, S.
    Tyler, A.
    Catlett, L.
    Hsyu, P.
    Huang, B.
    Healey, D.
    Rini, B. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Patel, P. H.
    Kondagunta, G. V.
    Redman, B. G.
    Hudes, G. R.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] A phase II study of intermittent sunitinib (S) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC)
    Rini, Brian I.
    Wood, Laura S.
    Elson, Paul
    Zhu, Hui
    Chittoria, Namita
    Mittal, Kriti
    Dreicer, Robert
    Gilligan, Timothy D.
    Shah, Shetal N.
    Garcia, Jorge A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345